Cochlear's $268m damages bill stands, says Fed Circuit

Australian ear implants manufacturer Cochlear must pay $268 million for infringing a patent owned by a US medical research organisation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ written description ruling overturns $1.2 billion award

26 August 2021 Kite Pharma has successfully persuaded the US Court of Appeals for the Federal Circuit to reverse a $1.2 billion win for the Bristol-Meyers Squibb owned Juno Therapeutics over a cancer treatment patent.

Medtech

Cochlear to pay $75m extra if patent judgment upheld

19 August 2020 Hearing implant manufacturer Cochlear has agreed to pay an additional $75 million to settle a patent infringement case if an original $268 million damages bill is upheld by the US Supreme Court.

Americas

No fees award for PTAB proceedings, rules Fed Circuit

5 June 2020 The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Cochlear's $268m damages bill stands, says Fed Circuit

More on this story

Editor's picks

Editor's picks

More features